secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001171843-21-005574
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q2 2021 net loss $29.8M; $83.6M stock offering; pipeline advances
------------------------------------------------------------------------

- Net loss $29.8M ($0.79 diluted EPS) vs $20.8M ($7.40) year ago; R&D spend $24.6M.
- Cash & investments $190.7M at June 30, 2021, down from $243.5M at Dec 2020.
- Gross proceeds of $83.6M from July 2021 follow-on stock offering (4.4M shares at $19.00).
- STOPS and CAM programs dosing in CHB cohorts; data expected H1 2022.
- CTA filed for ASO ALG-020572; NASH drug ALG-055009 CTA on track for Q3 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184321005574/0001171843-21-005574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184321005574/f8k_080521.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-005574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer